Effect of phosphodiesterase 4 (PDE4) inhibitors on eotaxin expression in human bronchial epithelial cells

Journal of Physiology and Pharmacology

Volumn 62, Issue 3, 2011, Pages 303-311

  Paplinska, M ^a   Chazan, R ^a   Grubek Jaworska, H ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Bronchial epithelial cells; Eotaxins; Interleukin 13; Interleukin 4; Phosphodiesterase 4 inhibitors; Tumor necrosis factor

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; DEXAMETHASONE; EOTAXIN; EOTAXIN 2; EOTAXIN 3; INTERLEUKIN 13; INTERLEUKIN 4; MESSENGER RNA; PHOSPHODIESTERASE IV INHIBITOR; RO 207124; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; BETA CHEMOKINE; CCL26 PROTEIN, HUMAN; CYTOKINE;

ARTICLE; BRONCHUS MUCOSA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BIOSYNTHESIS; BRONCHUS; CULTURE TECHNIQUE; CYTOLOGY; EOSINOPHIL; GENETICS; METABOLISM;

4-(3-BUTOXY-4-METHOXYBENZYL)-2-IMIDAZOLIDINONE; ANTI-INFLAMMATORY AGENTS; BRONCHI; CELL CULTURE TECHNIQUES; CHEMOKINE CCL11; CHEMOKINE CCL24; CHEMOKINES, CC; CYTOKINES; DEXAMETHASONE; EOSINOPHILS; EPITHELIAL CELLS; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; ROLIPRAM;

EID: 80355146380     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Hurley JH. Structure, mechanism, and regulation of mammalian adenylyl cyclase. J Biol Chem 1999; 274: 7599-7602.
2. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001; 108: 671-680.
3. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004; 84: 137-167.
4. Sanz MJ, Cortijo J, Morcillo EJ. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther 2005; 106: 269-297.
5. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008; 155: 308-315.
6. Wright LC, Seybold J, Robichaud A, Adcock IM, Barnes PJ. Phosphodiesterase expression in human epithelial cells. Am J Physiol Lung Cell Mol Physiol 1998; 275: L694-L700.
7. Fuhrmann M, Jahn HU, Seybold J, et al. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol 1999; 20: 292-302.
8. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366(9485): 563-571.
9. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154-161.
10. Rennard SI, Schachter N, Strek M, Rickard K, Amit O. Cilomilast for COPD: results of a 6-month, placebocontrolled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006; 129: 56-66.
11. Vestbo J, Tan L, Atkinson G, Ward J. UK-500,001 Global Study Team. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 2009; 33: 1039-1044.
12. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. M2-124 and M2-125 study groups: roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374(9691): 685-694.
13. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. M2-127 and M2-128 study groups. Roflumilast in moderate-tosevere chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374(9691): 695-703.
14. Lilly CM, Nakamura H, Kesselman H, et al. Expression of eotaxin by human lung epithelial cells induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997; 99: 1767-1773.
15. Rokudai A, Terui Y, Kuniyoshi R, et al. Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-alpha and IL-4 stimulated human lung fibroblast. Biol Pharm Bull 2006; 29: 1102-1109.
16. Lilly CM, Nakamura H, Belostotsky OI, et al. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2001; 163: 1669-1675.
17. Conroy DM, and Williams TJ. Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir Res 2001; 2: 150-156.
18. Rahman MS, Yamasaki A, Yang J, Shan L, Halayko AJ, Gounni AS. IL-17a induced eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, and p38) pathways. J Immunol 2006; 177: 4064-4071.
19. Badewa AP, Hudson CE, Heiman AS. Regulatory effects of eotaxin, eotaxin-2, and eotaxin-3 on eosinophil degranulation and superoxide anion generation. Exp Biol Med 2002; 227: 645-651.
20. Banwell ME, Tolley NS, Williams TJ, Mitchel TJ. Regulation of human eotaxin-3/CCL26 expression: modulation by cytokines and glucocorticoids. Cytokine 2002; 17: 317-323.
21. Watanabe K, Jose PJ, Rankin SM. Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages. J Immunol 2002; 168: 1911-1918.
22. Heinemann A, Hartnell A, Stubbs VE, et al. Basophil responses to chemokines are regulated by both sequential and cooperative receptor signaling. J Immunol 2000; 165: 7224-7233.
23. Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A, Springer MS. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996; 183: 2349-2354.
24. Brown IR, Kleimberg J, Marini M, Sun G, Bellini A, Mattoli S. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. Clin Exp Immunol 1998; 114: 137-146.
25. Ravensberg AJ, Ricciardolo FL, van Schadewijk A. Eotaxin-2 and eotaxin-3 expression with persistent eosinophilic bronchial inflammation in patients with asthma after challenge. J Allergy Clin Immunol 2005; 115: 779-785.
26. Berkman N, Ohnona S, Chung FK, Breuer R. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol 2001; 24: 682-687.
27. Jones NA, Boswell-Smith V, Lever R, Page CP. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005; 18: 93-101.
28. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005; 10: 1503-1519.
29. Eskandari N, Wickramasinghe T, Peachell PT. Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils. Br J Pharmacol 2004; 142: 1265-1272.
30. Clayton RA, Dick CA, Mackenzie A, et al. The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. Respir Res 2004; 5: 4.
31. Mokry J, Mokra D, Nosalova G, Beharkova M, Feherova Z. Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. J Physiol Pharmacol 2008; 59(Suppl 6): 473-482.
32. Busch CJ, Graveline AR, Jiramongkolchai K, Liu H, Sanchez LS, Bloch KD. Phosphodiesterase 3A expression is modulated by nitric oxide in rat pulmonary artery smooth muscle cells. J Physiol Pharmacol 2010; 6: 663-669.
33. Pang L, Knox AJ. Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. FASEB J 2001; 15: 261-269.
34. Sabatini F, Petecchia L, Boero S, et al. A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro. Pulm Pharmacol Ther 2010; 23: 283-291.
35. Santamaria LF, Palacios JM, Beleta J. Inhibition of eotaxinmediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram Br J Pharmacol 1997; 121: 1150-1154.
36. Liu J, Munoz NM, Meliton AY, et al. Beta2-integrin adhesion caused by eotaxin but not IL-5 is blocked by PDE-4 inhibition and beta2-adrenoceptor activation in human eosinophils. Pulm Pharmacol Ther 2004; 17: 73-79.
37. Nejman-Gryz P, Grubek-Jaworska H, Glapinski J, Hoser G, Chazan R. Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. J Physiol Pharmacol 2006; 57(Suppl 4): 229-239.
38. Silva PM, Alves AC, Serra MF, et al. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme. Br J Pharmacol 2001; 134: 283-294.
39. Stellato C, Matsukura S, Fal A, et al. Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J Immunol 1999; 163: 5624-5632.
40. Kobayashi I, Yamamoto S, Nishi N, et al. Regulatory mechanisms of Th2 cytokine-induced eotaxin-3 production in bronchial epithelial cells: possible role of interleukin 4 eceptor and nuclear factor-kappaB. Ann Allergy Asthma Immunol 2004; 93: 390-397.
41. Komiya A, Nagase H, Yamada H, et al. Concerted expression of eotaxin-1, eotaxin-2, and eotaxin-3 in human bronchial epithelial cells. Cell Immunol 2003; 225: 91-100.
42. Fujisawa T, Kato Y, Atsuta J, et al. Chemokine production by the BEAS-2B human bronchial epithelial cells: differential regulation of eotaxin, IL-8, and RANTES by TH2-and TH1-derived cytokines. J Allergy Clin Immunol 2000; 105: 126-133.
43. Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol 2001; 24: 755-761.
44. Matsukura S, Stellato C, Plitt JR, et al. Activation of eotaxin gene transcription by NFkB and STAT6 in human airway epithelial cells. J Immunol 1999; 163: 6876-6883.
45. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-370.
46. Chu YT, Chang TT, Jong YJ, et al. Suppressive effects of formoterol and salmeterol on eotaxin-1 in bronchial epithelial cells. Pediatr Allergy Immunol 2010: 21: 345-352.
47. Wuyts WA, Vanaudenaerde BM, Dupont LJ, Demedts MG, Verleden GM. Modulation by cAMP of IL-1beta-induced eotaxin and MCP-1 expression and release in human airway smooth muscle cells. Eur Respir J 2003; 22: 220-226.
48. Koga S, Morris S, Ogawa S, et al. TNF modulates endothelial properties by decreasing cAMP. Am J Physiol 1995; 268: C1104-C1113.
49. Emala CW, Kuhl J, Hungerford CL, Hirshman CA. TNFalpha inhibits isoproterenol-stimulated adenylyl cyclase activity in cultured airway smooth muscle cells. Am J Physiol 1997; 272: L644-L650.
50. Herve R, Schmitz T, Evain-Brion D, Cabrol D, Leroy MJ, Mehats C. The PDE4 inhibitor rolipram prevents NFkappaB binding activity and proinflammatory cytokine release in human chorionic cells. J Immunol 2008; 181: 2196-2202.
51. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factorkappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 2005; 315: 1188-1195.
52. Markova TP, Niwa A, Yamanishi H, Aragane Y, Higashino H. Antagonism of IL-4 signaling by a phosphodiesterase-4 inhibitor, rolipram, in human T cells. Int Arch Allergy Immunol 2007; 143: 216-224.
53. Chapman RW, House A, Jones H, et al. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats. Eur J Pharmacol 2007; 571: 215-221.
54. Celly CS, House A, Jones H, Hey JA, Chapman RW. Prevention and resolution of antigen-induced alterations in lung function of allergic Brown Norway rats by a PDE4 inhibitor, roflumilast. Am J Respir Crit Care Med 2005; 12: A95.